“No, I kind of made my team, and I also kind of said publicly that our target here is to get back to 100% of our market share by the end of the year.”

In context

“ycle. If you remember, last year, we launched EnSite X, and it was like a very large bolus of kind of upgrading and capital placements that we're making. We get a lot of good feedback on the system, both from the users and from the administration, especially the fact that it's an open system. So that's done very well. If you look at the consumable part of the U.S. growth, it was up in the mid-teens. So that, I guess, the term used was tear apart the EP growth rate. But again, it's a great market. We've got a great position and good recovery, and I expect to see this continuing throughout this year. And sorry, what was your other question? Joanne Wuensch: The other question had to do with the 75% recovery in Nutrition. Is that sort of your best case or is there more to go? Robert Ford: No, I kind of made my team, and I also kind of said publicly that our target here is to get back to 100% of our market share by the end of the year. A big driver of that is the manufacturing and the manufacturing kind of ramp up. And we started the manufacturing -- reopened the manufacturing process in July for specialty of last year and August and September for non-specialty. So that manufacturing has provided us the supply we need to fulfill the demand. We've got a very strong brand in Similac, and you're seeing that. So -- and as I said, I think maybe to Josh's question at the beginning, if you look at the different segments, first of all, if you start with WIC and non-WIC. In the WIC segment, we're back to leadership position or back to our position we had before the recall. And that was because we focused a lot on that Q3, Q4 time in that segment. So I guess, long-winded to say yes. I mean, we're still on target for that to b”